The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

XVI.ac

Imaging: Cavitating/cavitary lung nodule, mass or nodules (see also Iq, XIs, XIIi, XVIaa and XVIIp)

Publications

Rampinelli C, Spitaleri G, Passaro A, Pochesci A, Ancona E, De Marinis F

Lung Tissue Injury as an Atypical Response to Nivolumab in Non-Small Cell Lung Cancer.

American journal of respiratory and critical care medicine 2017 Nov 15;196;1349-1350 — 2017 Nov 15 — 1349-1350

Kimura H, Sone T, Murata A, Koba H, Tambo Y, Hara J, Abo M, Kasahara K

Long-lasting shrinkage in tumor mass after discontinuation of nivolumab treatment.

Lung cancer (Amsterdam, Netherlands) 2017 06;108;7-8 — 2017 06 — 7-8